Welcome!

News Feed Item

Data Demonstrating the Ability of ChemoFx® to Identify Platinum-Resistant Primary Ovarian Cancer Patients Prior to Treatment Published by the American Journal of Obstetrics and Gynecology

Precision Therapeutics, a life-science company dedicated to improving patient outcomes in gynecologic cancer, today announced that a study evaluating the ability of the ChemoFx® chemoresponse assay to identify resistance to first-line treatment in ovarian cancer has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).

The study, titled, A Chemoresponse Assay for Prediction of Platinum Resistance in Primary Ovarian Cancer, evaluated the association of ChemoFx® results with disease progression for 276 FIGO stage III-IV ovarian, fallopian and peritoneal cancer patients treated with the standard of care first-line therapy carboplatin/paclitaxel. Patients whose tumors were scored as resistant by the ChemoFx test to carboplatin, were at significantly increased risk of disease progression compared to those with non-resistant tumors (median PFS: 11.8 vs. 16.6 months, respectively, p<0.001). The association was confirmed after adjusting for other clinical factors (HR=1.71, 95% CI=1.12-2.62, p=0.013). In addition to identifying platinum-resistant patients, the study also demonstrated the ability of ChemoFx to identify agents to which a patient’s tumor is sensitive. For 59% of those patients whose tumors proved resistant to carboplatin, at least one other commonly utilized agent was determined by ChemoFx to be sensitive or intermediately sensitive, indicating that these patients may benefit from alternative clinically validated treatments. These results further demonstrate the capability of the ChemoFx test to inform treatment decisions beyond the carboplatin/paclitaxel standard of care, particularly in cases where patients are unlikely to respond to the routine treatment.

Dr. Thomas C. Krivak, M.D., assistant director of gynecologic oncology and director of clinical research in gynecologic oncology at Allegheny Health Network, Department of Obstetrics and Gynecology, in Pittsburgh PA, is the primary author of the study.

“What the findings of this study essentially mean for ovarian cancer patients is that resistance to standard platinum chemotherapy treatment can now be determined much earlier in the treatment pathway with the use of ChemoFx results,” said Dr. Krivak. “Earlier determination of platinum resistance may help physicians choose the more effective treatments upfront, minimizing exposure to ineffective and often expensive therapy. Additionally, having further information about the tumor and chemotherapy resistance could substantiate augmenting standard of care with a third chemotherapy or with targeted agents.”

In addition to these findings, a recent, prospective study on recurrent ovarian cancer patients showed a 14 month improvement in median overall survival when patients were administered treatments identified as sensitive by ChemoFx vs. the non-sensitive treatments. “The combination of information this test provides is invaluable to physicians who are compelled to choose from a range of equivalent treatment recommendations without prior knowledge of how an individual patient may respond to any given treatment,” said Sean McDonald, CEO of Precision. “The ability of this test to determine platinum resistance in primary ovarian cancer patients and to demonstrate longer overall survival by 14 months in recurrent ovarian cancer, makes it an instrumental tool in helping to improve outcomes in ovarian cancer patients.”

About ChemoFx®

ChemoFx® is a proprietary drug response marker, which categorizes an individual patient’s tumor response to a range of standard chemotherapeutic options. Recently published prospective data demonstrates a 14-month improvement in overall survival (OS) when recurrent ovarian cancer patients are treated with therapy indicated as ‘responsive’ by the assay. ChemoFx may also help identify platinum-resistant/refractory primary ovarian patients earlier in their treatment pathway, aiding physicians with the selection of effective treatment upfront for patients newly diagnosed. Precision Therapeutics currently receives ChemoFx® specimens from over 270 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care.

About Precision Therapeutics

Precision Therapeutics, a leading life-science company based in Pittsburgh, Pennsylvania, is dedicated to personalizing cancer care and improving patient outcomes. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. The company’s other leading products for personalized cancer care include:

  • BioSpeciFx®, a portfolio of clinically relevant molecular tests that provide information about drug response and patient prognosis.
  • GeneFx® Colon, an expression–based gene signature developed for FFPE tissue from stage II colon cancer patients. Following surgery, GeneFx Colon assesses a patient’s risk of recurrence within 5 years.

For more information, visit www.precisiontherapeutics.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
In his general session at 18th Cloud Expo, Lee Atchison, Principal Cloud Architect and Advocate at New Relic, discussed cloud as a ‘better data center’ and how it adds new capacity (faster) and improves application availability (redundancy). The cloud is a ‘Dynamic Tool for Dynamic Apps’ and resource allocation is an integral part of your application architecture, so use only the resources you need and allocate /de-allocate resources on the fly.
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of D...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
SYS-CON Events announced today that Outlyer, a monitoring service for DevOps and operations teams, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Outlyer is a monitoring service for DevOps and Operations teams running Cloud, SaaS, Microservices and IoT deployments. Designed for today's dynamic environments that need beyond cloud-scale monitoring, we make monitoring effortless so you...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.